Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

[18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer.

Pasqualetti F, Panichi M, Sollini M, Sainato A, Galli L, Morganti R, Chiacchio S, Marciano A, Zanca R, Mannelli L, Coraggio G, Sbrana A, Cocuzza P, Montrone S, Baldaccini D, Gonnelli A, Molinari A, Cantarella M, Mazzotti V, Ricci S, Paiar F, Erba PA.

Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):185-191. doi: 10.1007/s00259-019-04482-6. Epub 2019 Oct 16.

2.

[(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results.

Pasqualetti F, Panichi M, Sainato A, Matteucci F, Galli L, Cocuzza P, Ferrazza P, Coraggio G, Pasqualetti G, Derosa L, Sollini M, Mannelli L, Ortori S, Monzani F, Ricci S, Greco C, Fabrini MG, Erba PA.

Radiat Oncol. 2016 Jan 22;11:9. doi: 10.1186/s13014-016-0586-x.

3.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
4.

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.

Kneebone A, Hruby G, Ainsworth H, Byrne K, Brown C, Guo L, Guminski A, Eade T.

Eur Urol Oncol. 2018 Dec;1(6):531-537. doi: 10.1016/j.euo.2018.04.017. Epub 2018 May 23.

PMID:
31158100
5.

Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.

Bouman-Wammes EW, van Dodewaard-De Jong JM, Dahele M, Cysouw MCF, Hoekstra OS, van Moorselaar RJA, Piet MAH, Verberne HJ, Bins AD, Verheul HMW, Slotman BJ, Oprea-Lager DE, Van den Eertwegh AJM.

Clin Genitourin Cancer. 2017 Oct;15(5):e773-e782. doi: 10.1016/j.clgc.2017.03.009. Epub 2017 Mar 29.

PMID:
28462855
6.

Feasibility of 18F-fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans--first results.

Bucerius J, Schmaljohann J, Böhm I, Palmedo H, Guhlke S, Tiemann K, Schild HH, Biersack HJ, Manka C.

Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):815-20. doi: 10.1007/s00259-007-0685-x. Epub 2008 Jan 6.

PMID:
18183393
7.

Prognostic Value of [18F]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.

Cysouw M, Bouman-Wammes E, Hoekstra O, van den Eertwegh A, Piet M, van Moorselaar J, Boellaard R, Dahele M, Oprea-Lager D.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):406-410. doi: 10.1016/j.ijrobp.2018.02.005. Epub 2018 Feb 13.

PMID:
29559285
8.

Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT.

Gomez-Iturriaga A, Casquero Ocio F, Ost P, Fernandez I, Rodeño E, Llarena R, Garcia-Olaverri J, Ortiz de Zarate R, Cacicedo J, Ahtamon A, Bilbao P.

Eur J Cancer Care (Engl). 2019 Sep;28(5):e13093. doi: 10.1111/ecc.13093. Epub 2019 May 21.

PMID:
31115124
9.

Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.

Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, Nader M, Langsteger W, Loidl W.

J Nucl Med. 2013 Jun;54(6):833-40. doi: 10.2967/jnumed.112.110148. Epub 2013 Apr 4.

10.

Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.

Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.

BJU Int. 2015 Jun;115(6):874-83. doi: 10.1111/bju.12953. Epub 2015 Jan 21.

11.

Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.

Muldermans JL, Romak LB, Kwon ED, Park SS, Olivier KR.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):696-702. doi: 10.1016/j.ijrobp.2016.01.032. Epub 2016 Jan 29.

12.

Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.

Evangelista L, Cuppari L, Guttilla A, Gardi M, Agostini A, Ruggera L, Basso U, Saladini G.

Nucl Med Commun. 2018 Mar;39(3):260-267. doi: 10.1097/MNM.0000000000000808.

PMID:
29381584
13.

Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer.

Soldatov A, von Klot CAJ, Walacides D, Derlin T, Bengel FM, Ross TL, Wester HJ, Derlin K, Kuczyk MA, Christiansen H, Henkenberens C.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):95-104. doi: 10.1016/j.ijrobp.2018.08.066. Epub 2018 Sep 7.

PMID:
30201438
14.

68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy.

Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, Schiavina R, Lodi F, Morganti AG, Fanti S.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):11-19. doi: 10.1007/s00259-018-4066-4. Epub 2018 Jun 15.

PMID:
29905907
15.

Long-Term PSA Control with Repeated Stereotactic Body Radiotherapy in a Patient with Oligometastatic Castration-Resistant Prostate Cancer.

Pasqualetti F, Cocuzza P, Coraggio G, Ferrazza P, Derosa L, Galli L, Pasqualetti G, Locantore L, Boni R, Fabrini MG, Erba PA.

Oncol Res Treat. 2016;39(4):217-20. doi: 10.1159/000444906. Epub 2016 Mar 30.

PMID:
27160394
16.

Role of 18F-Choline PET/CT in guiding biopsy in patients with risen PSA levels and previous negative biopsy for prostate cancer.

Jiménez Londoño GA, García Vicente AM, Amo-Salas M, Fúnez Mayorga F, López Guerrero MA, Talavera Rubio MP, Gutierrez Martin P, González García B, de la Torre Pérez JA, Soriano Castrejón ÁM.

Rev Esp Med Nucl Imagen Mol. 2017 Jul - Aug;36(4):241-246. doi: 10.1016/j.remn.2017.01.014. Epub 2017 Mar 18. English, Spanish.

PMID:
28330596
17.

Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.

Conde-Moreno AJ, Herrando-Parreño G, Muelas-Soria R, Ferrer-Rebolleda J, Broseta-Torres R, Cozar-Santiago MP, García-Piñón F, Ferrer-Albiach C.

Clin Transl Oncol. 2017 May;19(5):553-561. doi: 10.1007/s12094-016-1563-4. Epub 2016 Oct 31.

PMID:
27796820
18.

(11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.

Graziani T, Ceci F, Castellucci P, Polverari G, Lima GM, Lodi F, Morganti AG, Ardizzoni A, Schiavina R, Fanti S.

Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1971-9. doi: 10.1007/s00259-016-3428-z. Epub 2016 Jun 8.

PMID:
27277279
19.

Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy.

Breeuwsma AJ, Rybalov M, Leliveld AM, Pruim J, de Jong IJ.

Q J Nucl Med Mol Imaging. 2012 Oct;56(5):440-6.

PMID:
23069923
20.

68Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery.

Marzec J, Becker J, Paulsen F, Wegener D, Olthof SC, Pfannenberg C, Schwenck J, Bedke J, Stenzl A, Nikolaou K, la Fougère C, Zips D, Müller AC.

Acta Oncol. 2019 Sep 27:1-8. doi: 10.1080/0284186X.2019.1669816. [Epub ahead of print]

PMID:
31559880

Supplemental Content

Support Center